A multicenter multistate modeling on the natural history of liver decompensation: Longitudinal analysis of 1777 patients.
BACKGROUND: Cirrhosis often remains silent until decompensation, after which survival deteriorates sharply. Contemporary, transition-aware estimates are limited, especially in Asian-predominant cohorts. We analyzed trajectories from compensated advanced chronic liver disease (cACLD) through sequential decompensations to death. METHOD: In this multicenter study, we analyzed retrospective data from an adult cohort with liver stiffness ≥15 kPa from vibration-controlled transient elastography across 19 institutions internationally. Decompensation included ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, or variceal bleeding. Multistate models were constructed to characterize patient trajectories across 4 main clinically meaningful states: baseline cACLD, first decompensation, a subsequent second decompensation, and death. Etiology-specific subgroup analyses were conducted, and the effects of univariable predictors on transitions were also examined. RESULTS: Among 1777 patients, 265 (14.9%) developed a first decompensation over a median follow-up of 4.25 years. In the main multistate analysis cohort, from baseline cACLD, first decompensation occurred in 215 patients at 3.10 per 100 person-years, while death occurred at a rate of 1.01 per 100 person-years. The rate of a second decompensation was higher following the first decompensation, at 42.73 per 100 person-years. Patients with alcohol-associated liver disease had the highest rate of progression from baseline to first decompensation, whereas patients with hepatitis B etiology had the lowest progression rate into a second decompensation following a first decompensating event. CONCLUSION: Most patients with cACLD remain compensated over 10 years of follow-up, but once decompensation occurs, trajectories accelerate, and survival worsens. Transition-aware, etiology-stratified estimates enable individualized prognostication and earlier risk-guided intervention, including timely transplant referral.
Authors
- Chitchai Rattananukrom (ORCID: https://orcid.org/0000-0002-1282-781X)
- Mazen Nourredin
- Jimmy Che‐To Lai (ORCID: https://orcid.org/0000-0002-5749-1598)
- Yuya Seko (ORCID: https://orcid.org/0000-0002-3658-5894)
- Apichat Kaewdech (ORCID: https://orcid.org/0000-0002-4058-5977)
- Mohammad Shadab Siddiqui
- Ming-Hua Zheng
- Nicole Shu Ying Tang (ORCID: https://orcid.org/0009-0004-6225-314X)
- Nicholas Syn
- Karn Wijarnpreecha
- Eunice X X Tan
- Akash Roy
- Toru Nakamura
- Masayuki Ueno
- Takefumi Kimura
- Yanhang Gao
- Rahul Kumar
- Cheng Han Ng
- Anand V Kulkarni
- Masato Yoneda
- Mark Muthiah
- Ken Liu
- Vincent L Chen
- Hirokazu Takahashi
- Daniel Q Huang
Institutions
- Kurume University (JP)
- The University of Sydney (AU)
- Prince of Songkla University (TH)
- Shinshu University (JP)
- National University of Singapore (SG)
- Saga University (JP)
- Chinese University of Hong Kong (HK)
- Khon Kaen University (TH)
- Jilin University (CN)
- Kyoto University (JP)
- University of Michigan (US)
- Royal Prince Alfred Hospital (AU)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Changi General Hospital (SG)
- Kyoto Prefectural University of Medicine (JP)
- Kurashiki Central Hospital (JP)
- Banner - University Medical Center Phoenix (US)
- Methodist Hospital (US)
- Michigan Medicine (US)
- Houston Institute for Clinical Research (US)
- First Hospital of Jilin University (CN)
- Shinshu University Hospital (JP)
- Asian Institute of Gastroenterology (IN)
- National University Hospital (SG)
- Mayo Clinic in Florida (US)
- National University Health System (SG)
- University of Arizona College of Medicine- Phoenix (US)
- Srinagarind Hospital, Faculty of Medicine, Khon Kaen University (TH)
- University of Virginia (US)
- Yokohama City University (JP)
Publication Details
- Journal
- PubMed
- Published
- 2026-10-01
- DOI
- https://doi.org/10.1097/hc9.0000000000001042
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00